

SUMMARY

In an aspect of the present disclosure, there is provided a use of a compound of the formula:




or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of a neurodegenerative disease, wherein a total dose of 0.1 mg/day to 5 mg/day of the compound, or pharmaceutically acceptable salt thereof is to be administered orally

In another aspect of the present disclosure, there is provided a use of a compound of the formula:



or a pharmaceutically acceptable salt thereof, for in the manufacture of a medicament for preventing the progression of mild cognitive impairment to Alzheimer's disease wherein a total dose of 0.1 mg/day to 5 mg/day of the compound, or pharmaceutically acceptable salt thereof is to be administered orally.


In a further aspect of the present disclosure, there is provided a pharmaceutical composition, comprising a compound of the formula:



or a pharmaceutically acceptable salt thereof with one or more pharmaceutically acceptable carriers, diluents, or excipients wherein the pharmaceutical composition contains a total dose of the compound of 0.1 mg to 5 mg.

DESCRIPTION

Accordingly, in one embodiment, the invention provides a compound of Formula I:




Formula I

,

or a pharmaceutically acceptable salt thereof, for use in treating a neurodegenerative disease wherein the compound, or pharmaceutically acceptable salt thereof is administered orally with a total dose of the compound of 0.1 mg/day to 5 mg/day.

In an embodiment, the invention provides a compound of Formula I:




Formula I

,

or a pharmaceutically acceptable salt thereof, wherein the compound, or pharmaceutically acceptable salt thereof is administered orally with a total dose of the compound of 0.1 mg/day to 5 mg/day for use in treating Alzheimer's disease.

In an embodiment, the invention provides a compound of Formula I:




Formula I

,

or a pharmaceutically acceptable salt thereof, wherein the compound, or pharmaceutically acceptable salt thereof is administered orally with a total dose of the compound of 0.1 mg/day to 5 mg/day for use in treating progressive supranuclear palsy.

In an embodiment, the invention provides a compound of Formula I:




Formula I

,

WHAT IS CLAIMED IS:

1. ~~A~~ Use of a compound of the formula:




,

or a pharmaceutically acceptable salt thereof, for ~~use in treating~~the manufacture of a medicament for the treatment of a neurodegenerative disease, wherein a total dose of 0.1 mg/day to 5 mg/day of the compound, or pharmaceutically acceptable salt thereof is to be administered orally ~~with a total dose of the compound of 0.1 mg/day to 5 mg/day~~.

2. The ~~compound, or pharmaceutically acceptable salt thereof for~~ use according to claim 1 wherein the neurodegenerative disease is Alzheimer's disease.

3. The ~~compound, or pharmaceutically acceptable salt thereof for~~ use according to claim 1 wherein the neurodegenerative disease is progressive supranuclear palsy~~palsey~~.

4. Use of a~~A~~ compound of the formula:



,

or a pharmaceutically acceptable salt thereof, for in the manufacture of a medicament for~~use in~~ preventing the progression of mild cognitive impairment to Alzheimer's disease wherein a total dose of 0.1 mg/day to 5 mg/day of the compound, or pharmaceutically acceptable salt thereof is to be administered orally ~~with a total dose of the compound of 0.1 mg/day to 5 mg/day~~.

5. The ~~compound, or pharmaceutically acceptable salt thereof for~~ use according to any one of claims 1 to 4 wherein the total dose of the compound is 0.25 mg/day to 5 mg/day, or 0.1 mg/day to 3 mg/day, or 0.25 mg/day to 3 mg/day, or 0.1 mg/day to 2 mg/day, or 0.25 mg/day to 2 mg/day, or 0.1 mg/day to 1 mg/day, or 0.25 mg/day to 1 mg/day.

~~6. The compound, or pharmaceutically acceptable salt thereof for use according to any one of claims 1 to 4 wherein the total dose of the compound is 0.1 mg/day to 3 mg/day.~~

~~7. The compound, or pharmaceutically acceptable salt thereof for use according to any one of claims 1 to 4 wherein the total dose of the compound is 0.25 mg/day to 3 mg/day.~~

~~8. The compound, or pharmaceutically acceptable salt thereof for use according to any one of claims 1 to 4 wherein the total dose of the compound is 0.1 mg/day to 2 mg/day.~~

~~9. The compound, or pharmaceutically acceptable salt thereof for use according to any one of claims 1 to 4 wherein the total dose of the compound is 0.25 mg/day to 2 mg/day.~~

~~10. The compound, or pharmaceutically acceptable salt thereof for use according to any one of claims 1 to 4 wherein the total dose of the compound is 0.1 mg/day to 1 mg/day.~~

~~11. The compound, or pharmaceutically acceptable salt thereof for use according to any one of claims 1 to 4 wherein the total dose of the compound is 0.25 mg/day to 1 mg/day.~~

~~12.~~6. The ~~compound, or pharmaceutically acceptable salt thereof for~~ use according to any one of claims 1 to 4 wherein the total dose of the compound is 3 mg/day, or 2.5 mg/day, or 2 mg/day, or 1.5 mg/day, or 1 mg/day, or 0.75 mg/day, or 0.5 mg/day, or 0.25 mg/day.

~~13. The compound, or pharmaceutically acceptable salt thereof for use according to any one of claims 1 to 4 wherein the total dose of the compound is 2.5 mg/day.~~

~~14. The compound, or pharmaceutically acceptable salt thereof for use according to any one of claims 1 to 4 wherein the total dose of the compound is 2 mg/day.~~

~~15. The compound, or pharmaceutically acceptable salt thereof for use according to any one of claims 1 to 4 wherein the total dose of the compound is 1.5 mg/day.~~

~~16. The compound, or pharmaceutically acceptable salt thereof for use according to any one of claims 1 to 4 wherein the total dose of the compound is 1 mg/day.~~

~~17. The compound, or pharmaceutically acceptable salt thereof for use according to any one of claims 1 to 4 wherein the total dose of the compound is 0.75 mg/day.~~

~~18. The compound, or pharmaceutically acceptable salt thereof for use according to any one of claims 1 to 4 wherein the total dose of the compound is 0.5 mg/day.~~

~~19. The compound, or pharmaceutically acceptable salt thereof for use according to any one of claims 1 to 4 wherein the total dose of the compound is 0.25 mg/day.~~

~~20.~~7. The ~~compound, or pharmaceutically acceptable salt thereof for~~ use according to any one of claims 1 to ~~19~~ 6 wherein the compound or pharmaceutically acceptable salt thereof is to be administered in unit dosage form.

~~21.~~8. The ~~compound, or pharmaceutically acceptable salt thereof for~~ use according to claim 7~~20~~ wherein the unit dosage form is selected from a capsule, tablet, gelcap, liquid solution, and liquid suspension.

~~22.~~9. The ~~compound, or pharmaceutically acceptable salt thereof for~~ use according to claim ~~219~~ 8 wherein the unit dosage form is a capsule or a tablet.


~~23. The compound, or pharmaceutically acceptable salt thereof for use according to claim 219 wherein the unit dosage form is a tablet.~~

~~24.~~10. The ~~compound, or pharmaceutically acceptable salt thereof for~~ use according to any one of claims 7-9~~20 to 23~~ wherein the total daily dose is to be administered in one unit dose.

~~25.~~11. The ~~compound, or pharmaceutically acceptable salt thereof for~~ use according to any one of claims 7-9~~20-23~~ wherein the total daily dose is to be administered in two unit doses.

~~26.~~12. The ~~compound, or pharmaceutically acceptable salt thereof for~~ use according to claim ~~25~~ 11 wherein the administration of each unit dose is separated by at least 8 hours.

27. A method of treating a neurodegenerative disease, comprising administering to a patient in need of such treatment a compound of the formula:



or a pharmaceutically acceptable salt thereof, wherein the compound or pharmaceutically acceptable salt thereof is administered orally with a total dose of the compound of 0.1 mg/day to 5 mg/day.

28. The method according to claim 27 wherein the neurodegenerative disease is Alzheimer's disease.

29. The method according to claim 27 wherein the neurodegenerative disease is progressive supranuclear palsey.

30. The method according to any one of claims 27 to 29 wherein the total dose of the compound is 0.25 mg/day to 5 mg/day.

31. The method according to any one of claims 27 to 29 wherein the total dose of the compound is 0.1 mg/day to 3 mg/day.

32. The method according any one of claims 27 to 29 wherein the total dose of the compound is 0.25 mg/day to 3 mg/day.

33. The method according to any one of claims 27 to 29 wherein the total dose of the compound is 0.1 mg/day to 2 mg/day.

34. The method according to any one of claims 27 to 29 wherein the total dose of the compound is 0.25 mg/day to 2 mg/day.

35. The method according to any one of claims 27 to 29 wherein the total dose of the compound is 0.1 mg/day to 1 mg/day.

36. The method according to any one of claims 27 to 29 wherein the total dose of the compound is 0.25 mg/day to 1 mg/day.

37. The method according to claim any one of claims 27 to 29 wherein the total dose of the compound is 3 mg/day.

38. The method according to any one of claims 27 to 29 wherein the total dose of the compound is 2.5 mg/day.

39. The method according to any one of claims 27 to 29 wherein the total dose of the compound is 2 mg/day.

40. The method according to any one of claims 27 to 29 wherein the total dose of the compound is 1.5 mg/day.

41. The method according to any one of claims 27 to 29 wherein the total dose of the compound is 1 mg/day.

42. The method according to any one of claims 27 to 29 wherein the total dose of the compound is 0.75 mg/day.

43. The method according to any one of claims 27 to 29 wherein the total dose of the compound is 0.5 mg/day.


44. The method according to any one of claims 27 to 29 wherein the total dose of the compound is 0.25 mg/day.

45. The method according to any one of claims 27 to 44 wherein the total daily dose is administered in one unit dose.

46. The method according to any one of claims 27 to 44 wherein the total daily dose is administered in two unit doses.

47. The method according to claim 46 wherein the administration of each unit dose is separated by at least 8 hours.

48. A method of preventing the progression of mild cognitive impairment to Alzheimer's disease, comprising administering to a patient in need of such treatment a compound of the formula:



or a pharmaceutically acceptable salt thereof, wherein the compound or pharmaceutically acceptable salt thereof is administered orally with a total dose of the compound of 0.1 mg/day to 5 mg/day.

49. The method according to claim 48 wherein the total dose of the compound is 0.25 mg/day to 5 mg/day.

~~50. The method according to claim 48 wherein the total dose of the compound is 0.1 mg/day to 3 mg/day.~~

~~51. The method according to claim 48 wherein the total dose of the compound is 0.25 mg/day to 3 mg/day.~~

~~52. The method according to claim 48 wherein the total dose of the compound is 0.1 mg/day to 2 mg/day.~~

~~53. The method according to claim 48 wherein the total dose of the compound is 0.25 mg/day to 2 mg/day.~~

~~54. The method according to claim 48 wherein the total dose of the compound is 0.1 mg/day to 1 mg/day.~~

~~55. The method according to claim 48 wherein the total dose of the compound is 0.25 mg/day to 1 mg/day.~~

~~56. The method according to claim 48 wherein the total dose of the compound is 3 mg/day.~~

~~57. The method according to claim 48 wherein the total dose of the compound is 2.5 mg/day.~~

~~58. The method according to claim 48 wherein the total dose of the compound is 2 mg/day.~~

~~59. The method according to claim 48 wherein the total dose of the compound is 1.5 mg/day.~~

~~60. The method according to claim 48 wherein the total dose of the compound is 1 mg/day.~~

~~61. The method according to claim 48 wherein the total dose of the compound is 0.75 mg/day.~~

~~62. The method according to claim 48 wherein the total dose of the compound is 0.5 mg/day.~~


~~63. The method according to claim 48 wherein the total dose of the compound is 0.25 mg/day.~~

~~64. The method according to any one of claims 48 to 63 wherein the total daily dose is administered in one unit dose.~~

~~65. The method according to any one of claims 48 to 63 wherein the total daily dose is administered in two unit doses.~~

~~66. The method according to claim 65 wherein the administration of each unit dose is separated by at least 8 hours.~~

~~67.~~13. A pharmaceutical composition, comprising a compound of the formula:



,

or a pharmaceutically acceptable salt thereof with one or more pharmaceutically acceptable carriers, diluents, or excipients wherein the pharmaceutical composition contains a total dose of the compound of 0.1 mg to 5 mg.

~~68.~~14. The pharmaceutical composition according to claim 13~~67~~ wherein the total dose of the compound is 0.25 mg to 5 mg, or 0.1 mg to 3 mg, or 0.25 mg to 3 mg, or 0.1 mg to 2 mg, or 0.25 mg to 2 mg, or 0.1 mg to 1 mg, or 0.25 mg to 1 mg.

~~69. The pharmaceutical composition according to claim 67 wherein the total dose of the compound is 0.1 mg to 3 mg.~~

~~70. The pharmaceutical composition according to claim 67 wherein the total dose of the compound is 0.25 mg to 3 mg.~~

~~71. The pharmaceutical composition according to claim 67 wherein the total dose of the compound is 0.1 mg to 2 mg.~~

~~72. The pharmaceutical composition according to claim 67 wherein the total dose of the compound is 0.25 mg to 2 mg.~~

~~73. The pharmaceutical composition according to claim 67 wherein the total dose of the compound is 0.1 mg to 1 mg.~~

~~74. The pharmaceutical composition according to claim 67 wherein the total dose of the compound is 0.25 mg to 1 mg.~~

~~75.~~15. The pharmaceutical composition according to claim 13~~67~~ wherein the total dose of the compound is 3 mg, or 2.5 mg, or 2 mg, or 1.5 mg, or 1 mg, or 0.75 mg, or 0.5 mg, or 0.25 mg.

~~76. The pharmaceutical composition according to claim 67 wherein the total dose of the compound is 2.5 mg.~~

~~77. The pharmaceutical composition according to claim 67 wherein the total dose of the compound is 2 mg.~~

~~78. The pharmaceutical composition according to claim 67 wherein the total dose of the compound is 1.5 mg.~~

~~79. The pharmaceutical composition according to claim 67 wherein the total dose of the compound is 1 mg.~~

~~80. The pharmaceutical composition according to claim 67 wherein the total dose of the compound is 0.75 mg.~~

~~81. The pharmaceutical composition according to claim 67 wherein the total dose of the compound is 0.5 mg.~~

~~82. The pharmaceutical composition according to claim 67 wherein the total dose of the compound is 0.25 mg.~~

~~83.~~16. The pharmaceutical composition according to any one of claims 13~~67~~ to 15~~82~~ wherein the total dose of the compound is contained in one unit dose.

~~84.~~17. The pharmaceutical composition according to any one of claims 13~~67~~ to 15~~82~~ wherein the total dose of the compound is contained in two unit doses.

~~85.~~18. The pharmaceutical composition according to any one of claims 13~~67~~ to 15~~82~~ wherein the total dose of the compound is contained in two unit doses with each unit dose containing equal amounts of the compound.

~~86. The pharmaceutical composition according to claim 83 wherein the one unit dose is administered once per day.~~

~~87. The pharmaceutical composition according to claim 84 wherein both unit doses are administered in a single day.~~

~~88. The pharmaceutical composition according to claim 85 wherein both unit doses are administered in a single day.~~

~~89. The pharmaceutical composition according to claim 87 wherein both unit doses are administered in a single day separated by at least 8 hours.~~

~~90. The pharmaceutical composition according to claim 88 wherein both unit doses are administered in a single day separated by at least 8 hours.~~